For the quarter ending 2026-03-31, IART had $1,761K increase in cash & cash equivalents over the period. -$5,045K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -4,617 | -1,704 | -5,404 | -509,366 |
| Depreciation and amortization | 38,430 | 38,430 | 38,522 | 74,880 |
| Non-cash lease expense | - | -81 | -307 | -599 |
| Non-cash impairment charges | - | 0 | 0 | 511,365 |
| Lease incentive | - | 1,299 | - | - |
| Deferred income tax provision (benefit) | 1,326 | -10,948 | -8,653 | -46,663 |
| Loss on disposal of property and equipment and construction in-progress | - | 0 | 4 | -494 |
| Share-based compensation | 5,165 | 5,838 | 5,580 | 7,165 |
| Amortization of debt issuance costs and expenses associated with debt refinancing | 995 | 1,015 | 1,315 | 3,275 |
| Non-cash lease adjustment | 330 | - | - | - |
| Loss on disposal of property and equipment | -90 | - | - | - |
| Change in fair value of contingent consideration and others | -1,293 | -6,685 | -14,441 | -203 |
| Accounts receivable | -13,645 | 16,452 | -22,507 | 6,540 |
| Inventories | 4,329 | 3,341 | 23,345 | 20,074 |
| Prepaid expenses and other current assets | 21,877 | -2,192 | -16,222 | 21,216 |
| Other non-current assets | -1,385 | -8 | -1,001 | -2,334 |
| Accounts payable, accrued expenses and other current liabilities | -19,186 | 23,020 | 5,782 | -2,078 |
| Contract liabilities | -630 | 685 | 371 | 2,344 |
| Other non-current liabilities | 369 | -21,460 | 1,760 | 2,544 |
| Net cash provided by (used in) operating activities | 9,803 | 11,816 | 40,906 | -2,338 |
| Purchases of property and equipment | 14,848 | 17,214 | 15,156 | 49,066 |
| Cash paid for business acquisitions, net of cash acquired | - | - | 0 | 0 |
| Purchases of intangible assets | - | 14,202 | - | - |
| Purchases of short-term investments | 0 | 0 | 0 | 8,502 |
| Proceeds from maturities of short-term investments | - | 7,000 | 0 | - |
| Cash paid for business acquisitions, net of cash acquired | - | 0 | - | - |
| Net (payment) proceeds on swaps designated as net investment hedges | - | 10,491 | 432 | - |
| Proceeds from exercise of stock options and employee stock purchase plan | - | 0 | 0 | 957 |
| Net cash used in investing activities | -14,848 | -34,907 | -15,588 | -57,568 |
| Proceeds from borrowings of long-term indebtedness | 44,500 | 49,700 | 603,700 | 67,300 |
| Payments on debt | 35,588 | 25,087 | 38,688 | 31,131 |
| Repayments of convertible debt | - | 0 | 574,983 | - |
| Payment of debt issuance costs | - | 134 | 75 | 3,855 |
| Purchase of treasury stock | - | 0 | 0 | 221 |
| Payments for contingent considerations | 0 | 0 | 0 | 16,451 |
| Proceeds from exercised stock options and employee stock purchase plan | 760 | - | - | - |
| Cash taxes paid in net equity settlement | 1,375 | 137 | 199 | 2,361 |
| Net cash provided by financing activities | 8,297 | 24,342 | -10,245 | 14,238 |
| Effect of exchange rate changes on cash and cash equivalents | -1,491 | 1,611 | -801 | 17,207 |
| Net increase (decrease) in cash and cash equivalents | 1,761 | 2,862 | 14,272 | -28,461 |
| Cash and cash equivalents at beginning of period | 235,048 | 232,186 | 246,375 | - |
| Cash and cash equivalents at end of period | 236,809 | 235,048 | 232,186 | - |
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)